SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Chesnot/Getty Images
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Thrives
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent’s foothold
July 28, 2022
 · 
3 min read
 · 
Tristan Manalac
Stem Cell Transplant Cures Oldest HIV Patient
City of Hope revealed that the oldest person living with HIV has achieved clinical remission after undergoing stem cell transplantation at the center more than three years ago.
July 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Benlysta is the first biologic to be approved for
FDA
FDA Approves First Biologic Benlysta to Treat Lupus Nephritis in Kids
FDA has approved GSK’s Benlysta (belimumab), making it the first biologic treatment for children ages 5 to 17 with lupus nephritis.
July 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of SOPA Images via Getty Images
Policy
DOJ Opens Probe Into Falsified Data Allegations Against Cassava
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
July 27, 2022
 · 
2 min read
 · 
Tristan Manalac
stop sign with black board backround
Drug Development
ObsEva Dropping Linzagolix, Plans Layoffs Following FDA Setback
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
July 27, 2022
 · 
3 min read
 · 
Tristan Manalac
Policy
Teva Proposes $5B Settlement for Thousands of Opioid Lawsuits
Teva expects to finalize and complete the documentation needed in the coming weeks, followed by a nationwide sign-on process for states, subdivisions and Native American tribes.
July 27, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Biogen/Ionis Scores NDA Nod for ALS Candidate
Ionis announced that the FDA has accepted its NDA for tofersen for SOD1-ALS. The application has been given the priority review designation and an action date of January 25, 2023.
July 26, 2022
 · 
2 min read
 · 
Tristan Manalac
Monkey pox vesicles in a hand
Policy
Are Companies Scrapping COVID Therapies for Monkeypox?
WHO declared the monkeypox outbreak a “public health emergency of international concern [PHEIC].” As COVID-19 wanes, Tonix, SIGA, Emergent Bio and others are now targeting monkeypox.
July 26, 2022
 · 
3 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Drug Development
FDA Hands Out Regulatory Nods to Novartis, AstraZeneca, HOOKIPA
Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted
July 25, 2022
 · 
4 min read
 · 
Tristan Manalac
Drug Development
VistaGen’s Nasal Spray for Social Anxiety Disorder Falls Short in Phase III Trial
VistaGenTherapeutics announced data showing that its nasal spray candidate for anxiety, depression and other central nervous system disorders, fell short of its primary endpoint.
July 22, 2022
 · 
3 min read
 · 
Tristan Manalac
Elderly woman sitting alone and looking sadly outside the window
Drug Development
Scientific Community Questions Anti-Amyloid Theory - the Basis for Seminal Alzheimer’s Work
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.
July 22, 2022
 · 
3 min read
 · 
Tristan Manalac
Dina Rudick/The Boston Globe
Policy
Biogen Quietly Resolves Whistleblower Case for $900M
The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.
July 21, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Vertex Sinks Potential $400M into Verve in Quest for Liver Disease Gene Therapy
Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.
July 21, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
VBL Becomes Latest Casualty in Heated Battle to Solve Ovarian Cancer
VBL’s ofra-vec candidate was primarily evaluated on its ability to improve PFS and OS in study participants—and delivered disappointing results for both measures.
July 20, 2022
 · 
3 min read
 · 
Tristan Manalac
John Schlueter_Foundation for Angelman Syndrome Th
Drug Development
Ultragenyx Buys GeneTx to Take Angelman ASO the Distance - Updated
The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.
July 19, 2022
 · 
4 min read
 · 
Tristan Manalac
Load More